IMPROVING SEVERE BURN RESUSCITATION OUTCOMES WITH ICATIBANT, AN FDA-APPROVED, SPECIFIC BRADYKININ B2 RECEPTOR ANTAGONIST

Metis Foundation, San Antonio TX

Investigators